TRT and Blood Pressure: What the Data Shows and Why Hematocrit Is Usually the Real Driver

TRT's effect on blood pressure has been studied with genuinely mixed results across the literature — some studies show mild increases, others show no significant change or even modest improvement, particularly in men whose low testosterone was linked to metabolic dysfunction. Understanding the mechanism that's actually implicated helps make sense of why the findings vary.

Hematocrit Is the More Consistent Mechanism

Rather than testosterone acting directly and consistently on blood vessel tone, the more reproducible pathway connecting TRT to blood pressure changes runs through hematocrit — the red blood cell concentration that TRT is well-documented to raise in a meaningful minority of users. Higher hematocrit increases blood viscosity, and thicker blood requires more cardiovascular effort to circulate, which can contribute to elevated blood pressure readings. This is why hematocrit monitoring, already standard TRT practice for its own clotting-risk reasons, is also relevant to blood pressure management specifically in men who develop this response.

Sodium and Fluid Retention

Testosterone and its aromatization to estradiol can influence sodium and fluid retention through effects on the renin-angiotensin-aldosterone system, a separate mechanism from the hematocrit pathway that has also been proposed as contributing to blood pressure changes in some TRT users, particularly at higher doses or with significant estradiol elevation from aromatization.

Why Results Are Mixed Across Studies

The inconsistency across trials likely reflects real population heterogeneity: men who develop significant hematocrit elevation on TRT are more likely to show blood pressure increases than men who don't, and baseline cardiovascular and metabolic health, delivery method (injectable peak-trough versus steadier gel-based delivery), and dose all plausibly affect who experiences a measurable change. TRAVERSE, the largest cardiovascular-outcomes trial for TRT, didn't identify blood pressure as a primary driver of its cardiovascular findings, though it did flag other hematocrit-adjacent signals like elevated clotting risk.

Practical Monitoring Implications

Given the hematocrit link, blood pressure is a reasonable addition to standard TRT monitoring alongside hematocrit itself, particularly in men who already have borderline or treated hypertension before starting therapy — a rise in either value is a signal worth discussing dose or delivery-method adjustments with the prescribing physician rather than treating as an unrelated, separate issue from the rest of the TRT monitoring panel.

Practical Takeaway

TRT's blood pressure effects aren't as uniform or well-established as the hematocrit and clotting risks discussed more prominently in TRT monitoring guidance, but the mechanism most consistently implicated — elevated hematocrit increasing blood viscosity — is already part of standard TRT bloodwork. Men who see hematocrit rise on TRT are a reasonable group to monitor blood pressure more closely, rather than assuming TRT's cardiovascular relevance begins and ends with the TRAVERSE trial's major-event findings.